Welcome to the Definitive Industry Forum for Chronic HBV Drug Development
While direct acting antiviral therapies have been effective in controlling viral replication, it’s clear that combination therapy with multiple mechanisms of action may be the key to achieving functional cure in chronic HBV, and the landscape for drug development in antiviral agents and immune modulation has never been more exciting.
The 2nd Chronic HBV Drug Development Summit united 20+ industry heavyweights as the definitive industry forum which focused exclusively on late translational through to phase II clinical trials for chronic HBV.
We heard from Gilead Sciences, Vir Biotechnology, VBI Vaccines, Drug Farm, Replicor, GSK, Assembly Biosciences and many more accelerating the frontier of novel therapies beyond the current standard of care to move the needle on functional cure.
From dissecting pivotal insight into sequencing multiple mechanisms of action acting on immune and viral targets to attain durable treatment, to leveraging advances in prediction of efficacy with novel serum markers including HBV RNA and core-related antigen, the HBV Summit is dedicated to driving progress in combination therapy paradigms.
Join us next year to forge successful industry collaborations in combination therapy for chronic HBV.